I missed this one. Good research. I hope Insmed can fulfill its pipeline during 7-year protection. Generic drugmakers are pain to many large drug firms. However, it will be benefit to all patients. I do believe Insmed will be bought in the future (5-7 years?). Many Insmed's high level management team believes the same. Also, Insmed is the leader in rhIGF-1/rhIGFBP-3 field. I will read more your links tonight.